Functional mechanism underlying cyclooxygenase-2 expression in rat small intestine following administration of indomethacin: Relation to intestinal hypermotility

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 1, 2005, Pages 38-45

  Tanaka, Akiko ^a   Matsumoto, Masahiro ^a   Hayashi, Yujiro ^a   Takeuchi, Koji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Atropine; Cyclooxygenase 2 expression; Intestinal damage; Intestinal motility; Non steroidal anti inflammatory drug; SC 560

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; AMPICILLIN; ATROPINE; CYCLOOXYGENASE 2; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GASTROINTESTINAL HEMORRHAGE; INTESTINE MOTILITY; INTESTINE MUCOSA; INTESTINE ULCER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMALL INTESTINE; ULCEROGENESIS; UPREGULATION;

EID: 12444344791     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03520.x     Document Type: Article

References (25)

1. Robert A, Asano T. Resistance of germ-free rats to indomethacin-induced intestinal inflammation. Prostaglandins 1987; 14: 333-41.
2. Fang WF, Broughto A, Jacobson ED. Indomethacin induced intestinal inflammation. Am. J. Dig. Dis. 1977; 22: 749-60.
3. Bjarnason I, Zanelli G, Smith T et al. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987; 93: 480-9.
4. Whittle BJR. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981; 80: 94-8.
5. Weissenborn U, Maedge S, Buettner D, Sewing KF. Indomethacin-increased gastrointestinal lesions in relation to tissue concentration, food intake and bacterial invasion in the rat. Pharmacology 1985; 30: 32-9.
6. Asako H, Kubes P, Wallace JL, Granger DN. Indomethacin-induced leukocyte adhesion in mesenteric venules; role of lipoxygenase products. Am. J. Physiol. 1992; 262: G903-8.
7. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993; 17: 641-62.
8. Konaka A, Nishijima M, Tanaka A, Kato S, Takeuchi K. Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol. Res. 1999; 40: 517-24.
9. Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 2002; 66: 30-41.
10. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroeneterology 2000; 119: 706-14.
11. Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br. J. Pharmacol. 2001; 132: 1565-73.
12. Tanaka A, Araki H, Hase S, Komoike Y, Takeuchi K. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J. Physiol. Paris 2001; 95: 21-7.
13. Tanaka A, Hase S, Miyazawa T, Takeuchi K. Up-regulation of COX-2 by inhibition of COX-1: a key to NSAID-induced intestinal damage. J. Pharmacol. Exp. Ther. 2002; 300: 754-61.
14. 2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig. Dis. Sci. 2002; 47: 894-904.
15. Smith CJ, Zhang Y, Koboldt CM et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. USA 1998; 95: 13313-18.
16. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclo-oxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47: 55-9.
17. Chan CC, Boyce S, Bridear C et al. Pharmacology of a selective cyclooxygenase-2 inhibitor L-745,337: a novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non-human primate stomach. J. Pharmacol. Exp. Ther. 1995; 274: 1531-7.
18. Feng L, Sun W, Xia Y et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch. Biochem. Biophys. 1993; 307: 361-8.
19. Iso JY, Sun X-H, Kao T-H, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res. 1995; 13: 2485-502.
20. Kunikata T, Miyazawa T, Kanatsu K, Kato S, Takeuchi K. Protective effect of thiaton, the anti-spasmodic drug, against indomethacin-induced intestinal ulceration in rats. Jpn. J. Pharmacol. 2002; 88: 45-54.
21. Brown JF, Tepperman BL, Hanson PJ, Whittle BJR, Moncada S. Differential distribution of nitric oxide synthase between cell fractions isolated from the rat gastric mucosa. Biochem. Biophys. Res. Comm. 1992; 184: 680-5.
22. Reuter BK, Davies NM, Wallace JL. Nonsteroidal antiinflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997; 112: 109-17.
23. Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K. Role of COX-1 and COX-2 inhibition in NSAID-induced intestinal damage in rats: relation to various pathogenic events. J. Pharmacol. Exp. Ther. 2002; 303: 1248-54.
24. Boughton-Smith N, Evans SM, Laszlo F, Whittle BJR, Moncada S. The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br. J. Pharmacol. 1993; 110: 1189-95.
25. Tanaka A, Ohno R, Hase S, Takeuchi K. Mechanism underlying up-regulation of COX-2 in rat small intestine under inhibition of COX-1. Gastroenterology 2002; 122: A-230.